Advances in HIV Treatment: When to Start Treatment Which Antivirals to Use
|
|
- Dayna Powers
- 5 years ago
- Views:
Transcription
1 Advances in HIV Treatment: When to Start Treatment Which Antivirals to Use Calvin Cohen MD Harvard Vanguard Medical Associates CRI New England Vice Chair, Science Steering Cmte, INSIGHT Boston MA
2 Learning Objectives Upon completion of this presentation, learners should be better able to: Apply HIV treatment guidelines to the practice of HIV medicine. Assess the remaining challenges to optimal health in HIV positive patients and the ongoing research related to these challenges.
3 Faculty and Planning Committee Disclosures Please consult your program book. Off-Label Disclosure There will be no off-label/investigational uses discussed in this presentation.
4 When to start HIV treatment Late clinical stages Early clinical stages < 200 > 500 High viral load Any viral load CD4 Adapted from Schechter M, JID 2004;190:
5 Mr. WTS He is a 35 year old male Has been seeing you for the past few years for his HIV No other medical concerns or issues CD4 counts consistently >500/mm 3 Viral load consistently < 5000 c/ml Has a steady partner who is HIV+ on meds Is willing to start treatment Wants your advice Are the possible medication side effects are worth it?
6 Mr. WTS 1. Yes he is ready and HIV treatment is appropriate 2. No need to start yet with this low viral load and high CD4, and his concern for possible medication side effects 3. I d refer him to the START study 4. I don t know what to recommend 5. Other?
7 Four Questions for Deciding When to Start Is there damage done by waiting to start treatment for patients with high T4 counts e.g., >500/mm 3? If yes, is the damage done by delaying HIV treatment completely reversible? At what CD4 count does the damage become irreversible? Are HIV treatments sufficiently ideal to treat everyone who is willing even those at very low risk of HIV-related illness?
8 Current Life Expectancy of HIV-Positive Patients Comparison of life expectancy of Athena cohort patients (n=4,174) to general population Years of Life Remaining Age at time of death Years lived Remaining Life Years General Population Asymptomatic HIV+ Patients Age at 24 weeks (years) van Sighem A, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 526.
9 CIPRAHT001: Randomized Trial of When to Start ART: Haiti Randomized clinical endpoint study of when to start therapy Treatment-naive No hx AIDS-defining illness CD (n=816) Immediate start with CD on ZDV/3TC + EFV Standard Treatment (Delay until CD4+ <200 or AIDS Primary endpoint: Survival Baseline Characteristics Early (n=408) Standard (n=408) Median age (years) Male (%) 41% 44% Median CD4+ (cells/mm 3 ) May 2009: DSMB review stopped study due to excess deaths in Standard Treatment arm Severe P, et al. 49 th ICAAC; San Francisco, CA; Sept , 2009; Abst. H-1230c.
10 CIPRAHT001: Clinical Endpoints Clinical Endpoints Early Rx Standard Hazard Ratio (p value) Death (.0011 ) Incident Tuberculosis (.0125 ) Infectious causes of death Early: 1 (gastroenteritis) Standard: 17 (7 gastroenteritis, 5 TB, 4 pneumonia, 1 cholangitis/sepsis) Severe P, et al. 49 th ICAAC; San Francisco, CA; Sept , 2009; Abst. H-1230c.
11 EACS Guidelines: When to Start ARV Therapy Condition Current CD4 + lymphocyte count C = CONSIDER. D = DEFER. R = RECOMMENDED >500 Asymptomatic HIV infection Consider Defer Symptomatic HIV disease (CDC B or C conditions) incl. tuberculosis Primary HIV infection C C Conditions (likely or possibly) associated with HIV, other than CDC stage B or C disease: HIV-associated kidney disease R R HIV-associated neurocognitive impairment R R Hodgkin's lymphoma R R HPV-associated cancers R R High risk for CVD (>20% estimated 10 yr risk) or history of CVD C C R R In serodiscordant couples early initiation of ART as one aspect of the overall strategy to reduce HIV transmission to the seronegative partner should be considered and actively discussed (October, 2011)
12 IAS-USA 2010: Guidelines for When to Start ARV Therapy Specific conditions Measure Symptomatic HIV disease Pregnancy High HIV-1 RNA Level (>100,000 copies/ml) Rapid CD4 count decline (>100 cells/mm 3 per year) Active hepatitis B or C* virus co-infection Active or high risk for cardiovascular disease* HIV-associated nephropathy Symptomatic primary HIV infection* Age > 60* Recommendation ART recommended regardless of CD4 cell count Risk for secondary HIV transmission is high* CD4 cell count 500 cells/mm 3 ART recommended CD4 cell count >500 cells/mm 3 ART should be considered * Differs from 2009 DHHS guidelines Unless patient is an elite controller (HIV-1 RNA <50 copies/ml) or has stable CD4 cell count and low-level viremia in the absence of ART Thompson MA, et al. JAMA 2010;304(3): ; US Department of Health and Human Services Guidelines; Revised December 1, Available at:
13 2012 DHHS Guidelines: Recommendations for Initiation of ART in Naïve Patients Clinical Category CD4 Cell Count (cells/mm 3 ) 2012 DHHS Guidelines Strength-Quality AIDS-defining illness Pregnancy HIV-associated nephropathy HIV/HBV coinfection Persons at risk of transmitting to sexual partners Age > 50 years old Any value Treat AI AI AII AII AI/AIII BIII <350 Treat AI Asymptomatic 350 to 500 Treat AII >500 Treat BIII Strength of Recommendation: A = Strong; B = Moderate; C = Optional Quality of Evidence for Recommendation: I = data from randomized controlled trials; II = data from well-designed nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = expert opinion Available at: Revision March 29, 2012.
14 Results of Three Large Observational Cohorts At what CD4 count does evidence of clinical harm (incr. risk of AIDS and/or death) begin when deferring starting Antiretroviral Therapy? ART-CC: < 350/mm 3 Cascade: < 500/mm 3 NA-ACCORD: Any delay, including > 500/mm 3 Sterne J, at al. 16th CROI; 2009; Montreal. Abstract 72LB., Funk MJ, et al. 18th IAC; Vienna, July 18-23, 2010; Abst. THLBB201., Kitahata M, et al. New Engl J Med 2009;360:
15 Rodger A, et al. 19th CROI; Seattle, WA; March 5-8, Abst SMART and ESPRIT: Mortality Risk of Patients on Suppressive ART vs. HIV negative population 3280 Non-IDU Patients from SMART and ESPRIT Most Recent Eligible Observed Death Rates and Overall SMRs Standardized by CD4 Age Count and Sex Cells/µL and Country >500 Person-years of follow-up Proportion % % Observed deaths Expected deaths SMR (95% CI) 1.77 ( ) 1.00 ( ) SMR: Standardized Mortality Ratio
16 SMART Naïve/Off Treatment Sub-study: Clinical Outcomes of (re-)starting ARVs Cum. Probability (X100) Opportunistic disease and death Hazard Ratio = 4.38 (95%.CI: ) p=0.009 Deferred ART Immediate ART No. at Risk Deferred ART 228 Immediate ART Months per 100 person years Emery S, et al. JID 2008; 197:
17 SMART Naïve/Off Treatment Sub-study: Clinical Outcomes of (re-)starting ARVs 25 Opportunistic disease and death 25 Composite endpoint Cum. Probability (X100) Hazard Ratio = 4.38 (95%.CI: ) p=0.009 Deferred ART Immediate ART Hazard Ratio = 5.08 (95% CI: ) p=0.001 No. at Risk Deferred ART 228 Immediate ART Continuous ART Intermittent ART Months No. at Risk Months Last CD4+ cell count (cells/ml) < > 500 Overall Event Rate * Event Rate * per 100 person years Emery S, et al. JID 2008; 197:
18 SMART: Non-AIDS event rates with Continuous vs. Intermittent ART Endpoint Continuous (n=2752) Intermittent (n=2720) HR (95% CI) P Value Any cause death ( ).007 Major CV, renal, or hepatic disease Fatal/nonfatal CV disease Fatal/nonfatal renal disease Fatal/nonfatal liver disease ( ) % 1.8% 1.6 ( ) % 0.3% 4.5 ( ) % 0.4% 1.4 ( ).46 Adapted from El-Sadr WM, et al. N Engl J Med 2006;355:
19 HPTN 052: Treatment as Prevention Randomized, placebo-controlled efficacy and safety study 13 sites in Africa, Asia, Americas: N=1763 HIV-positive patients in relationship with HIVnegative partner 97% Heterosexual CD N= 886 immediate HAART N=877 Delayed HAART until CD4<250 (or AIDS) N=1 transmission 96% risk reduction N=27 transmissions All received ongoing safe sex education/condoms Study stopped four years early by DSMB (May 2011) All 28 transmissions genetically linked to the positive partner All on delayed arm now offered HAART Available at: Accessed May 12, 2011.
20 Oral sex? The HOT study Cohort study of MSM Unprotected RAI** Protected RAI** Exclusively fellatio N = mo follow up Oral sex: No HIV infections observed despite lack of condom use (94%) Conclusions: Percent Rate of transmission via oral sex is low; 0 Unprotected RAI** Protected RAI** Exclusively fellatio Not zero: <0.8%. * HIV incidence determined in repeat testers ** RAI = receptive anal intercourse Page-Shafer K, et al. XIV Int AIDS Conference, Barcelona 2002, #4872; Balls et al We PpC2072, Bangkok 2004
21 START Study: Design HIV-infected individuals who are ART-naïve with CD4+ count > 500 cells/mm 3 Early ART group Initiate ART immediately following randomization N=2,000 Deferred ART group Defer ART until the CD4+ count declines to < 350 cells/mm 3 or AIDS develops N=2,000 Rate of primary endpoint in deferred group: 2.8 per 100 PY Non-AIDS : AIDS events = 4:1 Early ART reduces rate of primary endpoint by 28.8% 43% for AIDS and 24% for non-aids
22 What to Start?
23 Which Antiretrovirals: 2012 Currently Available (US) NRTIs Abacavir Didanosine NNRTIs Delavirdine Efavirenz PIs Atazanavir Darunavir Fusion Inhibitors Enfuvirtide Emtricitabine Etravirine Fos-Amprenavir Lamivudine Nevirapine (XR) Indinavir Stavudine Rilpivirine Lopinavir Entry inhibitors Tenofovir Nelfinavir Maraviroc Zidovudine Ritonavir Saquinavir Tipranavir Integrase inhibitors Raltegravir
24 EACS Guidelines: Ten Initial Combination Regimens 1 drug in column A 1 NRTI combination A B REMARKS Recommended EFV NVP NNRTI Ritonavirboosted PI ATV/r DRV/r LPV/r Integrase Inhibitor RAL C = CONSIDER. D = DEFER. R = RECOMMENDED (October 2011) ABC/3TC or TDF/FTC TDF/FTC ABC/3TC or TDF/FTC TDF/FTC TDF/FTC co-formulated ABC/3TC co-formulated EFV/TDF/FTC co-formulated ATV/r: 300/100 mg qd DRV/r: 800/100 mg qd LPV/r: 400/100 mg bid or 800/200 mg qd RAL: 400 mg bid
25 EACS Guidelines: 9 Alternative Initial Combination Regimen 1 drug in column A 1 NRTI combination A B REMARKS Alternative SQV/r FPV/r MVC ZDV/3TC ddl/3tc or FTC SQV/r: start with 500/100 mg then change to 1000/100 mg bid after one week FPV/r: 700/100 mg bid or 1400/200 mg qd ZDV/3TC co-formulated C = CONSIDER. D = DEFER. R = RECOMMENDED (October 2011)
26 2012 DHHS Guidelines: What to Start: Four Preferred Preferred Regimens: Regimens with optimal and durable efficacy, favorable tolerability and toxicity profile, and ease of use NNRTI: EFV/TDF/FTC EFV caution for women given risk of birth defects when EFV used in first trimester PI: ATV/r + TDF/FTC DRV/r (once daily) + TDF/FTC Int: RAL + TDF/FTC ATV/r should not be used in patient who require >20mg omeprazole equivalent per day RAL dosing BID Comments: TDF should be used with caution in patients with renal insufficiency Available at: Revision March 29, 2012.
27 2012 DHHS Guidelines: What to Start: Four Preferred Preferred Regimens: Regimens with optimal and durable efficacy, favorable tolerability and toxicity profile, and ease of use NNRTI: EFV/TDF/FTC EFV caution for women given risk of birth defects when EFV used in first trimester PI: ATV/r + TDF/FTC DRV/r (once daily) + TDF/FTC Int: RAL + TDF/FTC Preferred Regimen for Pregnant Women LPV/r (twice daily) +ZDV/3TC ATV/r should not be used in patient who require >20mg omeprazole equivalent per day RAL dosing BID Once-daily LPV/r is not recommended in pregnant women Comments: TDF should be used with caution in patients with renal insufficiency Available at: Revision March 29, 2012.
28 2012 DHHS Guidelines: What to Start: 14 Alternatives Alternative Regimens - that are effective and tolerable but have potential disadvantages compared with preferred regimens. An alternative regimen may be the preferred regimen for some patients. NNRTI Based Regimens: EFV + ABC/3TC (BI) PI Based Regimens (alphabetically) ATV/r + ABC/3TC (BI) DRV/r + ABC/3TC (BIII) INSTI Based Regimen RAL + ABC/3TC (BIII) RAL dosed twice daily Comments for abacavir: Should not be used in patients who test positive for HLA-B5701 Use with caution in patients with known high risk of cardiovascular disease or with pretreatment HIV RNA >100,000 copies/ml Available at: Revision March 29, 2012.
29 2012 DHHS Guidelines: What to Start: 14 Alternatives Alternative Regimens - that are effective and tolerable but have potential disadvantages compared with preferred regimens. An alternative regimen may be the preferred regimen for some patients. NNRTI Based Regimens: EFV + ABC/3TC (BI) RPV/TDF/FTC (BI) RPV + ABC/3TC (BIII) Use RPV with caution in patients with pretreatment HIV RNA >100,000 copies/ml Use of proton pump inhibitors is contraindicated with RPV PI Based Regimens (alphabetically) ATV/r + ABC/3TC (BI) DRV/r + ABC/3TC (BIII) FPV/r (QD or BID) + ABC/3TC or TDF/FTC (BI) LPV/r (QD or BID) + ABC/3TC or TDF/FTC (BI) INSTI Based Regimen RAL + ABC/3TC (BIII) RAL dosed twice daily Comments for abacavir: Should not be used in patients who test positive for HLA-B5701 Use with caution in patients with known high risk of cardiovascular disease or with pretreatment HIV RNA >100,000 copies/ml Available at: Revision March 29, 2012.
30 What to Start: The Basis for These Rankings There is no single perfect regimen Each regimen has Pros and Cons If there was, this would be a much shorter talk What data justifies these rankings?
31 ACTG 5142: EFV with better response vs. LPV/r for VL > 5 log Screening viral load 100,000 copies/ml Patients at Risk (n) Riddler SA, et al. N Engl J Med 2008;358:
32 DRV/r and ATV/r in ARV-Naïve Patients: Higher Response Rates than LPV/r Patient Percent <50 copies/ml ARTEMIS 1 (ITT, TLOVR)* 96 weeks 71 n=346 LPV/r QD or BID 79 n=343 DRV/r 800/100 QD CASTLE 2 (ITT, NC=F) 96 weeks 68 LPV/r 400/100 BID 74 n=443 n=440 ATV/r 300/100 QD *Estimated difference in response vs LPV/r for superiority: ITT = 8.3% (95% CI 1.8;14.7, P=0.012) Adapted from: 1. Mills A, et al. AIDS May 29, 2009 [Epub ahead of print]; 2. Molina J-M, et al. 48th ICAAC/46th IDSA, Washington, DC, 2008.Abst. H-1250d
33 ACTG 5202: ATV/r vs. EFV Week 96 % with Virologic Suppression HR 1.26 (0.76,2.05) Percent without Virologic Failure 83.4% 85.3% 89% 89.8% HR 1.13 (0.82,1.56) ABC/3TC HR 1.01 (0.70,1.46) TDF/FTC CD4 Change (cells/mm 3 ) P= Daar E, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 59LB.
34 STARTMRK: Design and Outcomes at Week 192 Randomized 1:1 To RAL:EFV Plus TDF/FTC Double Blind design N=281 RAL + TDF/FTC N=282 EFV + TDF/FTC Discontinuation: N=58 (20.6%) 5 lack of efficacy 13 AEs 8 lost to follow-up 32 miscellaneous Discontinuation: N=85 (29.9%) 8 lack of efficacy 26 AEs 17 lost to follow-up 34 miscellaneous 223 (79.4%) Completed 197 (69.9%) Completed DeJesus E, et al. IDSA 2011, 405;
35 STARTMRK: RAL vs. EFV + TDF/FTC % with HIV RNA <50 c/ml (NC=F) Percent of Patients with HIV RNA <50 Copies/mL Δ (RAL-EFV) [95% CI]=+9.0 [1.6, 16.4] Non-Inferiority p-value < Number of Contributing Patients Weeks Raltegravir group Efavirenz group DeJesus E, et al. IDSA 2011, 405; Rockstroh J, et al. EACS 2011, PS1/1.
36 STARTMRK: Four Year Follow Up Rates of Failure Proportion of Patients (%) with: CD4 Cell Count, Change from BL (cells/mm 3 ) Observed VF AE Related DC Both Trt Related DC=Failure NC=F Obs Failure RAL (N=281) 9% 5% 14% 24% EFV (N=282) 15% 9% 24% 33% RAL - EFV 6.0* (0.1, 12.2) 4.0 (NA) 10.1* (3.3, 17.0) 9.0* (1.6,16.4) 59.8 (24.1, 95.4) Observed Failure (OF): Patients who discontinued tx due to lack of efficacy were considered as failures thereafter Tx-Related Discontinuation=Failure: Patients who discontinued tx due to lack of efficacy or AE were considered as failures thereafter. Non-Completer=Failure (NC=F): Patients who discontinued tx regardless of reason were considered as failures thereafter DeJesus E, et al. IDSA 2011, 405; Rockstroh J, et al. EACS 2011, PS1/1. * p-value for non-inferiority <0.001
37 Absence of Primary Protease Mutations in First-Line Therapy With PI/r Study n NRTI backbone PI/r Week Genotypes Primary PI mutations d4t + 3TC LPV d4t + 3TC LPV d4t + 3TC LPV d4t + 3TC LPV TDF + 3TC LPV Solo ABC + 3TC FPV Staccato ddi + d4t SQV BMS d4t-xr + 3TC ATV ARTEMIS TDF + FTC LPV or DRV 96 NA 0 CASTLE TDF + FTC LPV or ATV * *in ATV/r arm 1. Gulick R, et al. 7th ICDTHI, 2004; Abstract P Kempf D, et al. J InfDis 2004;189:51; 3. Cahn P, et al. 1st IAS, 2001; Abstract Feinberg J, et al. 14th IAC, 2002; Abstract TuPeB Molina JM, et al. 15th IAC, 2004; Abstract WePeB MacManus S, et al. AIDS 2004;18:65; 7. Ananworanich J, et al. 3rd IAS, 2005; Abstract WePe4.4C12; 8. Malan N, et al. CROI 2006; Abstract 107LB. 9. Mills T, et al. 48th ICAAC/46th IDSA, 2008; Abstract H-1250c. 10. Molina J-M, et al. 48th ICAAC/46th IDSA, 2008; Abstract H-1250d.
38 Adherence: On time Pharmacy Refills by Number of Tablets per Day Single Tablet Regimen Multi-Tablet Regimen p< % better adherence to STR: 70% vs.59% Percentage of Patients p<0.01 p<0.01 p<0.01 N = <60% >60-79% 80-94% % Cohen CJ et al. ESPACOMP Nov 2011, Utrecht. Oral 315 Adherence to Antiretroviral Therapy
39 A5202: Two NRTIs plus EFV / ATV/r: Impact of baseline viral load and CD4 count ABC/3TC TDF/FTC 1 HIV RNA 100,000 c/ml HIV RNA < 100,000 c/ml Probability of remaining free of virologic failure n=98 35 VF n=78 23 VF n=80 19 VF n= VF n=39 6 VF n= VF n=23 5 VF n= VF n=80 6 VF n=83 17 VF n=70 9 VF n= VF n=55 8 VF n= VF n=20 2 VF n= VF 0 CD4 (cells/mm 3 ) Adapted from Grant P, et al. 18th CROI; Boston, MA; February 27-March 2, Abst <50 50 to < to <
40 Comparisons of Safety and Adverse Events
41 D:A:D Study: The Controversy about NRTI MI risk Recent Exposure*: yes/no Relative risk (95% CI) Similar concern raised about LPV/r 0.6 ZDV ddi d4t 3TC ABC TDF #PYFU: 138,109 74,407 95, ,009 53,300 39,157 #MI: * Recent use=current or within the last 6 months. Adapted from Lundgren JD, et al. 16th CROI; Montreal, Canada; February 8-11, Abst. 42LB.
42 ACTG 5202: TDF/FTC vs. ABC/3TC with Atazanavir/r vs. EFV: Change in Creatinine Clearance 10 Wk 48, p=0.17 Wk 96, p=0.33 Wk 48 Wk 96 Wk 48, p=0.001 Wk 96, p<0.001 Median Change in Calculated Creatinine Clearance, (ml/min) ATV/r 4.3 EFV 7.8 ATV/r p-values: ATV/r vs. EFV EFV ABC/3TC TDF/FTC N= Backbone Daar E, et al. CROI 2010, 59LB
43 A5224s: Mean Percent Change in Lumbar Spine Bone Mineral Density NRTI Component: Primary Analysis NNRTI/PI Component: Secondary Analysis Lumbar Spine Percent BMD Change from Week 0 to 192 ABC/3TC TDF/FTC EFV ATV/r P=0.004 P=0.035 Hip BMD: Significantly greater percent decline with TDF/FTC than ABC/3TC; not significant for NNRTI/PI No significant difference in fracture rate between arms McComsey, G, et al. CROI 2010, 106LB.
44 A5224s: Change in Visceral Adipose Tissue VAT change from week 0 (%) CT Results: Mean percent change in VAT (ITT) NRTI Component Secondary Analysis P = 0.55 NNRTI/PI Component Secondary Analysis P = ATV/r average gain 1.8 kg trunk fat; EFV average gain 0.7 kg trunk fat. McComsey, G, et al. 18th CROI; Boston, MA; February 27-March 2, Abst. 77.
45 STARTMRK Metabolic Study: RAL vs. EFV at Week 96 Lipid Changes p <0.001 * P =0.025 * No sig diff in total/hdl ratio Mean Percent Change in Appendicular Fat Dexa substudy (n=111) Week 96, >20% loss of limb fat 3/37 (8%) on RAL 2/38 (5%) on EFV DeJesus E, et al. 17th CROI; San Francisco, CA; February 16-19, Abst. 720.
46 Rilpivirine: ECHO and THRIVE Wk 48 Outcome by Adherence and Viral Load Adherent Suboptimally Adherent BL VL <100K BL VL >100K BL VL <100K BL VL >100K RPV EFV RPV EFV RPV EFV RPV EFV Virologic Responder 95% 92% 87% 92% 47% 39% 31% 37% Virologic Failure 3% 4% 10% 4% 21% 11% 50% 17% Other D/C 2% 5% 2% 4% 31% 50% 19% 46% Adapted from Rimsky L, et al. 50th ICAAC; Boston, MA; September 12-15, 2010; Abst. H-1810.
47 Mr. WTS Mr. S transfers to your practice He tested positive a year ago Ready to start treatment but didn t feel his other clinician really knew HIV Says he hears you really do CD4 is 290, Viral load 75,163 c/ml Genotype showed no resistance mutations
48 Mr WTS What do you recommend? 1. TDF/FTC/EFV 2. TDF/FTC/ATV/r 3. TDF/FTC/DRV/r 4. TDF/FTC/RAL 5. TDF/FTC/RPV 6. Other 7. I don t know
49 Summary When to Start: Consensus to start when CD4 count >350/mm 3 How high above 350 an ongoing discussion Which to Start: Multiple Randomized trials identify several regimens with: Efficacy: Durablevirologic suppression Safety: Fewer side effects vs. prior ARVs Which one an ongoing discussion
When to Start HIV Treatment? Which Treatments to Start?
When to Start HIV Treatment? Which Treatments to Start? Calvin Cohen MD Harvard Medical School Harvard Vanguard Medical Associates CRI New England Vice Chair, Science Steering Cmte, INSIGHT Boston USA
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationFirst-Line Antiretroviral Therapy for Treatment and Prevention:
First-Line Antiretroviral Therapy for Treatment and Prevention: The Past, Present and Future Best Options Joel Gallant, MD, MPH Johns Hopkins University School of Medicine IAS-USA Guidelines 7/2008: When
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationNew Frontiers for Treatment Strategies for HIV Care
New Frontiers for Treatment Strategies for HIV Care Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Disclosures:
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationHIV: Approach to the Treatment-Naïve Patient
HIV: Approach to the Treatment-Naïve Patient Paul E. Sax, M.D. Clinical Director, Division of Infectious Diseases Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Approach
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationProfessor Jeffery Lennox
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationI. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationThe 17th Conference on Retroviruses and Opportunistic Infections* ARV Therapies and Therapeutic Strategies A CME Newsletter
* CROI 2010 * February 16-19, 2010 San Francisco, CA Course Director Calvin Cohen, MD, MS Research Director, CRI New England Clinical Instructor, Harvard Medical School Boston, Massachusetts Faculty Jürgen
More informationProfessor José Arribas
19 th Annual Conference of the British HIV Association (BHIVA) Professor José Arribas Hospital La Paz, Madrid, Spain 16-19 April 2013, Manchester Central Convention Complex Can we live without nucleosides?
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationJosep Mallolas Hospital Clínic Barcelona
Nuevos paradigmas en la infección VIH Josep Mallolas Hospital Clínic Barcelona 1. Do you believe, I have to start ARV therapy? Incidence and Mortality of AIDS in Spain HIV and NON-AIDS complications HIV
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationL infettivologia del 3 millennio: AIDS ed altro
L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie
More informationFat redistribution on ARVs: dogma versus data
Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationEACS 2011 October 12-15, 2011 Belgrade, Serbia IDSA October 20-23, 2011 Boston, Massachusetts Course Director. Faculty
EACS 2011 October 12-15, 2011 Belgrade, Serbia IDSA October 20-23, 2011 Boston, Massachusetts Course Director John Bartlett, MD Professor, Johns Hopkins University School of Medicine Baltimore, Maryland
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationAntiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationHIV Virology & Resistance
Themes Viral load Tropism Drug resistance HIV Virology & Resistance Anna Maria Geretti Institute of Infection & Global Health The HIV Virology Timeline HIV-1 isolated HIV replicates at high levels throughout
More information16th Conference on Retroviruses and Opportunistic Infections ARV Therapies and Therapeutic Strategies A CME Newsletter
CROI 2009 8-11, February 2009 Montréal, Canada Course Director John Bartlett, MD Professor of Medicine Johns Hopkins University Baltimore, MD Faculty Rafael Campo, MD Professor of Clinical Medicine University
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationDidactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012
Didactic Series Update: 2012 HIV Treatment Guidelines Daniel Lee, MD August 30, 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationAntiretroviral Therapy: When and What to Start. Joe Eron, MD University of North Carolina at Chapel Hill School of Medicine
Antiretroviral Therapy: When and What to Start Joe Eron, MD University of North Carolina at Chapel Hill School of Medicine Learning Objectives As a results of participating in this activity participants
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationOptimizing ARV For Women
Optimizing ARV For Women Kathleen E. Squires, MD W Paul and Ida H Havens Professor of Infectious Diseases Director, Division of Infectious Diseases Sidney Kimmel Medical College of Thomas Jefferson University
More informationSources of slides and information. roi/main.html. CME slide kit : Rush University Medical Center
Sources of slides and information www.clinicaloptions.com/hiv com/hiv http://www.hivandhepatitis.com/2010_conference/chivandhepatitis conference/c roi/main.html CME slide kit : Rush University Medical
More informationIntegrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University
Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless
More information13 th Conference on Retroviruses and Opportunistic Infections (CROI)
REPORT FROM 13 th Conference on Retroviruses and Opportunistic Infections (CROI) February 5 8, 5 2006 Denver, CO 1 Tipranavir Significantly Reduces Concentrations of Other ARVs -10 % change PK -30-50 -70-68
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationWhat s New. In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group
What s New In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group Guidelines for our Online Meeting Room You will be listening to
More informationHIV10 November 7-11, 2010 Glasgow, Scotland
HIV1 November 7-11, 21 Glasgow, Scotland Course Director Calvin Cohen, MD, MS Research Director, CRI New England Clinical Instructor, Harvard Medical School Boston, Massachusetts Faculty José Arribas,
More informationStatistical issues in HIV trial design. Andrew Hill Senior Visiting Research Fellow Liverpool University
Statistical issues in HIV trial design Andrew Hill Senior Visiting Research Fellow Liverpool University Type 1 error It is statistically significant! (after 100 different statistical tests) Type 1 error:
More informationEuropean Guidelines. for the Clinical Management and Treatment of HIV Infected Adults
European Guidelines for the Clinical Management and Treatment of HIV Infected Adults 2005 These Euroguidelines result from the comparison of guidelines from several European countries and from a discussion
More information2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationNew HIV EACS and Italian Guidelines
Original Article HIV correlated pathologies and other infections Marco Borderi New HIV EACS and Italian Guidelines Infectious Disease Unit - S. Orsola-Hospital - University of Bologna Corresponding author:
More information